Abstract
COVID-19 associated public health measures and school closures exacerbated symptoms in some children and youth with attention-deficit hyperactivity disorder (ADHD). Less well understood is how the pandemic influenced patterns of prescription stimulant use. We conducted a population-based study of stimulant dispensing to children and youth ≤ 24 years old between January 1, 2013, and June 30, 2022. We used structural break analyses to identify the pandemic month(s) when changes in the dispensing of stimulants occurred. We used interrupted time series models to quantify changes in dispensing following the structural break and compare observed and expected stimulant use. Our main outcome was the change in the monthly rate of stimulant use per 100,000 children and youth. Following an initial immediate decline of 60.1 individuals per 100,000 (95% confidence interval [CI] − 99.0 to − 21.2), the monthly rate of stimulant dispensing increased by 11.8 individuals per 100,000 (95% CI 10.0–13.6), with the greatest increases in trend observed among females, individuals in the highest income neighbourhoods, and those aged 20 to 24. Observed rates were between 3.9% (95% CI 1.7–6.2%) and 36.9% (95% CI 34.3–39.5%) higher than predicted among females from June 2020 onward and between 7.1% (95% CI 4.2–10.0%) and 50.7% (95% CI 47.0–54.4%) higher than expected among individuals aged 20–24 from May 2020 onward. Additional research is needed to ascertain the appropriateness of stimulant use and to develop strategies supporting children and youth with ADHD during future periods of long-term stressors.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Public health restrictions imposed during the COVID-19 pandemic exacted a considerable toll on the mental health of children and youth [1, 2]. Those with ADHD were especially vulnerable to the loss of daily routines associated with school closures and other public health measures, with several studies finding increases in the severity of ADHD symptoms, anxiety, increased screen time, and negative mood [3,4,5,6,7,8,9,10]. Specifically, a study of more than 600 youth with ADHD and individually-matched comparators found that those with ADHD were more likely to exhibit sleeping difficulties, fear and negative emotions related to the risk of family illness, trouble with remote learning, rule-breaking behavior related to COVID-19 restrictions and family conflict [11]. Moreover, youth with ADHD were less prepared for the next school year and less responsive to protective environmental variables’ mitigating effects, such as school engagement and parental monitoring [11]. Further, a study of 118 youth with ADHD and a comparison group of 110 individuals without ADHD found that those with ADHD had fewer routines, higher negative affect and more difficulties with remote learning than those without ADHD [12]. These challenges were amplified among adolescents with ADHD requiring school accommodations, with nearly one-third of these adolescents’ parents indicating that remote learning was very challenging, compared with 18% of parents of adolescents with ADHD and no learning plan and 4% of parents with neither ADHD nor pre-existing learning difficulties [12].Remote learning may have therefore exacerbated academic difficulties already experienced by youth with ADHD [13, 14].
However, comparatively little research has examined whether pandemic-associated challenges for children and youth with ADHD impacted prescription stimulant use. This is important, as stimulants are the mainstay of pharmacotherapy for children and youth with ADHD, and the rapid transition to virtual care may have disrupted ongoing ADHD care and decreased access to stimulant pharmacotherapy [15, 16]. In Ontario specifically, physician billing codes for virtual assessments were introduced in March 2020 [17], with virtual visits comprising the majority of outpatient mental health visits for children and adolescents during the ensuing months of the COVID-19 pandemic [18]. There were no restrictions placed on stimulant prescribing during this period. In order to facilitate treatment continuity following the transition to virtual care, Health Canada implemented changes to the Controlled Drugs and Substances Act that permitted pharmacists to verbally accept, adapt, extend and transfer prescriptions for patients using controlled substances such as stimulants [19]. Although the proportion of pharmacist submitted stimulant claims increased 21.5 fold following the amendment, the absolute number of stimulant claims submitted by pharmacists remained low, increasing from an average of 0.02% of all submitted claims per month during the pre-pandemic period to 0.42% of all submitted claims per month between March 22, 2020 and December 19, 2021 [19].
In contrast to concerns about decreased stimulant access, the loss of school-based and non-pharmacological services during the pandemic may have promoted increased stimulant use and amplified pre-pandemic trends of increased stimulant use among children and youth described in other studies [20, 21] This is important, as stimulants have been associated with adverse effects such as decreased appetite, weight loss, sleep difficulties, and irritability [22, 23]. Stimulants have also been associated with growth suppression and rare adverse effects such as psychosis and priapism [22,23,24,25,26]. Cardiovascular adverse effects are generally limited to modest increases in blood pressure and heart rate [27]. The risk of cardiovascular adverse effects may be heightened with concomitant use of antipsychotics or fluoroquinolone antibiotics [28, 29]. Furthermore, the increased use of stimulants among females of child-bearing age and during pregnancy has raised concerns about the potential for adverse neonatal outcomes following in utero exposure to these drugs [30,31,32]. Although some studies have found associations between in utero stimulant exposure and cardiac malformations, gastroschisis, omphalocele, and transverse limb deficiency, the absolute risks appear small [33, 34]. Moreover, antenatal exposure to stimulants was not associated with neurodevelopmental or growth outcomes in a large cohort study [35], and a systematic review of eight cohort studies found no convincing evidence associating prenatal prescription stimulant exposure with clinically significant adverse effects [36]. Another potential concern with prescription stimulants is the potential for misuse among young adults. Past research has found that non-medical use of these drugs increased from 3.7% to 4.5% of surveyed university students in Canada between 2013 and 2016 [37, 38]. Reports of serious adverse events with non-medical stimulant use, such as critical care hospitalizations, emergency department visits for stimulant toxicity and death, highlight the risks associated with this practice [39].
However, despite concerns about interruptions in the continuity of care and the potential risks of stimulants, available studies examining the impact of COVID on stimulant use in children and youth are hampered by limited follow-up and little clarity regarding whether changes in stimulant use varied by sex, age and socioeconomic status [40,41,42]. Accordingly, we studied the impact of the COVID-19 pandemic on prescription stimulant use among the entire population of individuals aged 0–24 in Ontario, home to approximately 40% of Canadian children and youth [43].
Methods
Setting
We conducted a population-based study of all Ontario residents aged 0–24 years between January 1, 2013, and June 30, 2022. As in other jurisdictions, Ontario students experienced several cycles of school openings and closures during the pandemic (see supplemental appendix for timeline), and experienced the most frequent fully-remote school closures in Canada, totalling approximately 220 days during the pandemic [44, 45].
Data sources
We used Ontario’s administrative health databases which were linked using unique encrypted identifiers and analyzed at ICES. These databases are valid and reliable for routine sociodemographic data, physician billing claims and primary diagnoses, and undergo routine rigorous quality checks for completeness and consistency by the Data Quality and Information Management team at ICES [46, 47]. We identified stimulant prescriptions using the Narcotics Monitoring System database, which contains comprehensive records of prescriptions for stimulants dispensed from community pharmacies in Ontario, regardless of payer. We used the ICES Corporate Provider Database to determine prescriber specialty and the Registered Persons Database, a registry of all individuals eligible for the publicly-funded Ontario Health Insurance Plan, to ascertain demographic characteristics for all children and youth dispensed stimulants over the study period. The use of data in this project was authorized under Sect. 45 of Ontario’s Personal Health Information Protection Act, which does not require review by a Research Ethics Board.
Study population and outcomes
For each month of the study period, we defined our study population as all Ontario residents aged 24 and younger who were alive on the first day of the month. Our primary outcome was the monthly rate of stimulant use per 100,000 children and youth, defined as the number of individuals dispensed a stimulant (i.e., amphetamine, dextroamphetamine, lisdexamfetamine, methylphenidate; supplemental Table 1) in each month divided by the population of children and youth aged 0–24 for that period. To ascertain whether the characteristics of children and youth changed following the COVID-19 pandemic, we compared demographic characteristics and prescriber type (i.e., general practitioner, developmental pediatrician and/or pediatric psychiatrist, pediatrician, other) for individuals receiving stimulants during the pre-pandemic (January 2013–March 2020) and post-pandemic (April 2020–June 2022) periods.
Statistical analyses
We used standardized differences (SD) to compare demographic characteristics between individuals receiving a stimulant during the pre- and post-pandemic periods, with differences greater than 0.1 considered meaningful [48].
We used several approaches to explore whether stimulant dispensing to children and youth changed during the pandemic. First, rather than assuming that changes in stimulant dispensing occurred immediately following the imposition of public health restrictions and school closures in March 2020, we used structural break analyses to test for shifts in the intercept and/or slope of the time series, following seasonal adjustment to account for the lower use of stimulants in the summer months and 15% trimming of the dataset [49, 50]. This approach also allowed us to determine whether other breaks in the time series were associated with events unrelated to the pandemic that would need to be accounted for in subsequent modelling. Next, we determined the crude relative percent changes in stimulant dispensing from the month prior to the structural break to the month following the structural break and to June 2022, the end of our study period.
Because the relative percent change does not account for prior trends, temporal correlation and seasonality, we used interrupted time series analyses to quantify the immediate step change and change in monthly stimulant dispensing trend per 100,000 individuals aged 0–24 years following the structural break(s) [51, 52]. Specifically, we used a dummy variable to denote the timing of the structural break(s), an indicator for time to account for the underlying temporal trend in the data and an interaction term between time and the dummy variable representing the structural break to estimate the change in stimulant dispensing trend following the structural break. Our models also included dummy variables for month to account for seasonality, and a variable denoting implementation of a publicly-funded pharmacare program known as OHIP + that covered the prescription costs of all individuals aged 24 and under beginning in January 2018 [53]. We also calculated expected stimulant dispensing rates for the period following the structural break in the absence of COVID-19 using data between January 2013 and the month preceding the structural break, with time, month, and the indicator for OHIP + as model predictors. We then determined the relative percent changes between the observed and predicted stimulant dispensing rates and estimated associated 95% confidence intervals using the Poisson distribution. To explore heterogeneity in the impact of the pandemic, we stratified all analyses by sex, age category (5–9 years, 10–14 years, 15–19 years, 20–24 years), neighbourhood income quintile and urban versus rural residence, defined on the first day of the month of interest. We tested for autocorrelation to a maximum of 12 lags using the Cumby-Huizinga test for autocorrelation and estimated all models using Newey-West standard errors to account for autocorrelation up to 12 lags and heteroscedasticity [54, 55]. All analyses were completed using Stata version 17.0 (StataCorp LLC, College Station, TX, USA), R Studio, and EViews 12.
Results
During our nearly 10-year study period, 308,583 individuals aged 24 or younger were dispensed a stimulant. The rate of stimulant dispensing among children and youth increased 62.6% (95% confidence interval [CI] 60.6–64.5%) between January 2013 (1015.8 per 100,000 individuals) and June 2022 (1651.2 per 100,000 individuals). Most stimulant-treated children and youth were male (n = 196,445; 63.7%), and the median age was 13 years (interquartile range: 8–18 years) (Table 1). Individuals between the ages of 0 and 4 comprised less than 2% of children and youth dispensed a stimulant during the study period (Table 1, supplemental Fig. 1). Compared with the pre-pandemic period, there was an increase in the proportion of stimulant recipients that were female (32.5% vs. 39.6%; SD = 0.15) and those aged 20–24 years (17.6% vs. 25.1%; SD = 0.18). Conversely, there was a decrease in the proportion of stimulant recipients that were male (67.5% vs. 60.4%; SD = 0.15), aged 0–4 years (1.8% vs. 0.7%; SD = 0.15) and aged 5–9 years (32.1% vs. 21.0%; SD = 0.25) (Table 1). Changes in prescriber type were also observed following the pandemic, with an increase in the proportion of stimulant prescriptions written by general practitioners (38.9 vs. 45.5%; SD = 0.14) and a corresponding decline in the share of prescriptions written by pediatricians (41.2 vs. 35.9%; SD = 0.11) (Table 1). Methylphenidate was the most commonly dispensed stimulant during the study period (Table 1). However, methylphenidate accounted for a decreased proportion of stimulant prescriptions in the post-pandemic period relative to the pre-pandemic period (55.6% vs. 65.6%; SD = 0.21). Conversely, lisdexamfetamine accounted for an increased proportion of stimulant prescriptions dispensed in the post- relative to the pre-pandemic period (35.3% vs. 23.0%; SD = 0.27). Stimulant dispensing generally followed a seasonal pattern, with higher use during the school months (Fig. 1) and less cyclicity among those aged 20 to 24 relative to younger children and youth (Fig. 3).
Stimulant dispensing rate level change immediately following COVID-19
Structural break analyses identified endogenous breaks in January 2018, the month of OHIP + implementation, and April 2020, the month following the declaration of a public health emergency and school closures. We observed a modest relative percent decrease in stimulant dispensing to children and youth immediately following the structural break, with rates decreasing 9.0% (95% CI − 10.0% to − 7.9%) between March 2020 and May 2020 (1470.8 vs. 1338.8 per 100,000 population, respectively) (Table 2). In analyses stratified by age, there was an immediate increase in stimulant dispensing among individuals aged 20–24 (1118.3 vs. 1288.7 individuals per 100,000 population), corresponding to a relative percent increase of 15.2% (95% CI 12.2–18.4%) (Table 2). Conversely, stimulant dispensing declined in other age strata and remained below pre-pandemic levels for children aged 5–9 throughout our post-pandemic follow-up period (Fig. 3; supplemental Table 12).
Following interrupted time series modelling, there was an immediate decline in stimulant dispensing of 60.1 per 100,000 (95% CI − 99.0 to − 21.2) associated with the April 2020 structural break. (Fig. 1) (Table 2). In stratified analyses, the largest declines were observed among males (− 108.8 per 100,000; 95% CI − 156.6 to − 61.0) and individuals between the ages of 5 and 9 (− 188.2 per 100,000; 95% CI − 231.5 to − 144.9) (Table 2). In addition, a socioeconomic gradient was observed, with the largest decline occurring among residents of low-income neighbourhoods (− 92.0 per 100,000; 95% CI − 118.1 to − 66.0). Conversely, the level change in stimulant dispensing rates was least pronounced among individuals in the highest-income neighbourhoods (− 37.8 per 100,000 individuals; 95% CI − 115.6–39.8). In contrast to other strata, an immediate increase in stimulant dispensing was observed among individuals 20–24 years of age (91.1 per 100,000; 95% CI 35.9–146.3) (Table 2).
Change in stimulant dispensing rate trends following COVID-19
Stimulant dispensing to children and youth increased in the months following the April 2020 structural break, increasing 12.3% (95 CI 11.0–13.5%) between the month preceding the structural break (i.e., March 2020) and June 2022 (1470.8 vs. 1651.2 individuals per 100,000 population) (Table 2). In stratified analyses, the largest increases were observed among females (946.9 vs. 1293.5 individuals per 100,000) (Fig. 2) and individuals aged 20–24 (1118.3 vs. 1841.9 per 100,000) (Fig. 3), with relative percent increases in stimulant dispensing of 36.6% (34.0–39.2%) and 64.7% (60.6–68.8%), respectively (Table 2).
Interrupted time series models estimated that the monthly rate of stimulant dispensing increased by 11.8 individuals per 100,000 (95% CI 10.0–13.6) after April 2020, with the largest changes in monthly trend observed among females (16.9 individuals per 100,000; 95% CI 16.2–17.7) and individuals aged 20–24 (25.7 individuals per 100,000; 95% CI 23.3–28.0) (Table 2, Figs. 2 and 3). In terms of socioeconomic status, the monthly rate of stimulant dispensing increased most among children and youth living in the highest income neighbourhoods (15.5 individuals per 100,000; 95% CI 12.8–18.1) and least among residents of the lowest income neighbourhoods (9.3 individuals per 100,000; 95% CI 7.6–10.9) (Table 2). In contrast to other strata, monthly stimulant use continued to decline after April 2020 in children aged 5–9 years (− 3.3 individuals per 100,000; 95% CI − 5.0 to − 1.6) (Table 2, Fig. 3).
Comparison of actual and predicted stimulant dispensing rates following the COVID-19 pandemic
Overall, the observed mean rate of stimulant dispensing between April 2020 and June 2022 was slightly higher than predicted (1464.3 vs. 1440.6 individuals per 100,000), with a relative percent difference of 1.6% (95% CI 0.45–2.8%). However, there was variability in the pattern of change observed, with generally lower than expected rates through May 2021 and observed rates consistently exceeding predicted rates from June 2021 onward (Supplemental Appendix). Although this pattern was similar among most strata of children and youth, observed rates were between 3.9% (95% CI 1.7–6.2%) and 36.9% (95% CI 34.3–39.5%) higher than predicted among females from June 2020 onward (Supplemental Appendix). In addition, youth between the ages of 20 and 24 had stimulant dispensing rates that were between 7.1% (95% CI (4.2–10.0%) and 50.7% (95% CI 47.0–54.4%) higher than expected from May 2020 onward (Supplemental Appendix). Conversely, stimulant dispensing to children aged 5–9 years remained below predicted values at all points during the pandemic (Supplemental Appendix).
Discussion
In our population-based study, we observed a large increase in stimulant dispensing to children and youth over the study period. This increase may in part reflect the expansion in diagnostic criteria for ADHD in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), published in May 2013 [24]. With respect to COVID-19, we observed an initial decrease in stimulant dispensing to Ontario children and youth in the early period of the pandemic, followed by a rapid return to pre-pandemic rates in the ensuring months and greater than expected use from June 2021 onward. A similar pattern was observed in a study summarizing stimulant dispensing trends in 47 countries, with greater than expected use beginning in the second quarter of 2021 following a decline early in the pandemic [42]. Our work builds upon these findings by demonstrating considerable heterogeneity in the patterns of stimulant use during the pandemic, with larger post-pandemic increases in stimulant use observed among females, youth between the ages of 20 and 24 and children and youth living in the highest income neighbourhoods. These findings correspond with the changing demographics of stimulant use in the post-pandemic period, with a greater proportion of children and youth receiving stimulants being female and older. Our finding of increased lisdexamfetamine dispensing during the COVID period may reflect trends in stimulant prescribing favouring long-acting formulations and a perception of less misuse potential with this drug [23, 56].
The initial decrease in stimulant use around April 2020 aligns with earlier research demonstrating lower than expected outpatient mental health service use in Ontario children and youth at this point in the pandemic and a lack of severe problem behaviours among youth with ADHD early in the course of the pandemic [10, 18]. In addition, it is possible that this decline reflects parental decisions to discontinue stimulant medication in their children while schools were closed or during remote learning. This assertion may explain the lower than expected stimulant use among children aged 5–9 years, as elementary schools were closed for a large portion of our study period. Conversely, the lack of decline and greater than expected stimulant use during the pandemic among those aged 20–24 could reflect the ability of these individuals to access stimulants without parental involvement. However, a concern with the increased use of stimulants in this specific population is the potential for non-medical misuse of these drugs. A 2020 systematic review summarizing studies of stimulant diversion and misuse found that these practices were most commonly undertaken to enhance academic performance among young adults between the ages of 18 and 25 [39]. Because of the potential for serious adverse effects with the non-medical use of stimulants, additional research is required to ascertain whether stimulant diversion and misuse increased during the pandemic.
Our finding of a greater post-pandemic increase in stimulant use among females relative to males is consistent with studies from other jurisdictions. Specifically, an Australian study of individuals aged 18 years and under found higher than expected stimulant dispensing among females than males [57]. Similarly, a United States study found a substantial increase in stimulant dispensing among females of all age groups in 2020 and 2021, with decreased stimulant dispensing observed among males aged 19 years and younger [58]. Another United States study found that females comprised a greater proportion of first ADHD diagnoses in the pandemic compared to pre-pandemic years [59]. Reasons for sex-based differences in stimulant use following the pandemic are unknown. Because females may be more likely than males to present with the inattentive phenotype of ADHD [60], one possibility is that the transition to virtual learning rendered such symptoms more readily detectable by parents tasked with helping children navigate this new learning paradigm. Similarly, the stressors and disruptions associated with the pandemic may have undermined previously described compensatory behaviours undertaken by females with ADHD to mask symptoms [61].
We also observed differences in stimulant dispensing according to socioeconomic status, with a smaller immediate decline in use followed by a greater increase in the ensuing months among children in the highest relative to the lowest-income neighbourhoods. Other research has described similar trends, with individuals from high-income neighbourhoods returning to pre-pandemic rates of ADHD-related care during the pandemic, while those from the lowest-income neighbourhoods experienced continued disruptions in care [59]. One possible reason for these differences relates to socioeconomic disparities in the ability to work from home, favouring individuals from high-income neighbourhoods [62]. For these families, working from home could have facilitated greater recognition of student challenges with remote learning and subsequent access to stimulant pharmacotherapy to improve performance. Moreover, the transition to virtual health care may have exacerbated inequities in accessing ADHD-related care, with higher-income families having greater access to the resources required to schedule and attend virtual appointments [63]. In addition, a study from the United States found that adolescents from low-income families were significantly more likely than adolescents from high-income families to receive no remote or online learning and significantly less likely to engage in class meetings online [12]. Although it is unknown if a similar pattern occurred in Ontario, less engagement with school may also account for findings of lower stimulant use in lower-income children during the pandemic. Finally, one study found differences in post-COVID symptom manifestation according to socioeconomic status, which may have prompted increased medical attention and treatment, with adolescents from higher-income families being more likely to display opposition and defiant symptoms than those from low-income families [5].
Strengths of our study include complete stimulant claims data for all children and youth in Ontario and greater than two years of post-pandemic follow-up, facilitating a long-term evaluation of patterns in stimulant use during this period. However, our study has some limitations. First, we could not ascertain the appropriateness of stimulant use. Second, our databases do not include information regarding individual income, race, or ethnicity, important determinants of prescription stimulant use in other studies which merit additional research[64, 65]. Third, we could not determine the reasons for differential changes in stimulant use in our study population. Further qualitative and quantitative research is needed to understand these changes and inform programming and policy. Fourth, we did not longitudinally examine whether COVID-19 changed the dose or duration of stimulant. Finally, our study was conducted in a single Canadian province, potentially limiting the generalizability of our findings.
In summary, we found increased stimulant dispensing to children and youth during the pandemic, particularly among females, individuals aged 20–24 and those in the highest-income neighbourhoods. Furthermore, these increases have been sustained during the pandemic. Additional research is needed to ascertain the appropriateness of stimulant use as a response to challenges with virtual learning and the disruption in routines associated with the pandemic and to develop strategies supporting healthy coping behaviours during future periods of long-term stressors during which abrupt disruptions in daily living may occur.
Data availability
The data set from this study is held securely in coded form at ICES. While data sharing agreements prohibit ICES from making the data set publicly available, access may be granted to those who meet pre-specified criteria for confidential access, available at www.ices.on.ca/DAS. The full data set creation plan and underlying analytic code are available from the authors upon request, understanding that the programs may rely upon coding templates or macros unique to ICES.
References
Kauhanen L, Wan Mohd Yunus WMA, Lempinen L et al (2023) A systematic review of the mental health changes of children and young people before and during the COVID-19 pandemic. Eur Child Adolesc Psychiatry 32:995–1013
Madigan S, Racine N, Vaillancourt T et al (2023) Changes in depression and anxiety among children and adolescents from before to during the covid-19 pandemic: a systematic review and meta-analysis. JAMA Pediatr 177:567–581
Rogers MA, MacLean J (2023) ADHD symptoms increased during the Covid-19 pandemic: a meta-analysis. J Atten Disord 27:800–811
Stavridou A, Stergiopoulou AA, Panagouli E et al (2020) Psychosocial consequences of COVID-19 in children, adolescents and young adults: a systematic review. Psychiatry Clin Neurosci 74:615–616
Breaux R, Dvorsky MR, Marsh NP et al (2021) Prospective impact of COVID-19 on mental health functioning in adolescents with and without ADHD: protective role of emotion regulation abilities. J Child Psychol Psychiatry 62:1132–1139
Swansburg R, Hai T, MacMaster FP, Lemay JF (2021) Impact of COVID-19 on lifestyle habits and mental health symptoms in children with attention-deficit/hyperactivity disorder in Canada. Paediatr Child Health 26:e199–e207
Masi A, Mendoza Diaz A, Tully L et al (2021) Impact of the COVID-19 pandemic on the well-being of children with neurodevelopmental disabilities and their parents. J Paediatr Child Health 57:631–636
Zhang J, Shuai L, Yu H et al (2020) Acute stress, behavioural symptoms and mood states among school-age children with attention-deficit/hyperactive disorder during the COVID-19 outbreak. Asian J Psychiatr 51:102077
Sciberras E, Patel P, Stokes MA et al (2022) Physical Health, media use, and mental health in children and adolescents with ADHD during the COVID-19 pandemic in Australia. J Atten Disord 26:549–562
Sibley MH, Ortiz M, Gaias LM et al (2021) Top problems of adolescents and young adults with ADHD during the COVID-19 pandemic. J Psychiatr Res 136:190–197
Rosenthal E, Franklin-Gillette S, Jung HJ et al (2022) Impact of COVID-19 on youth with ADHD: predictors and moderators of response to pandemic restrictions on daily life. J Atten Disord 26:1223–1234
Becker SP, Breaux R, Cusick CN et al (2020) Remote learning during COVID-19: examining school practices, service continuation, and difficulties for adolescents with and without attention-deficit/hyperactivity disorder. J Adolesc Health 67:769–777
DuPaul GJ, Gormley MJ, Laracy SD (2013) Comorbidity of LD and ADHD: implications of DSM-5 for assessment and treatment. J Learn Disabil 46:43–51
Murray DW, Molina BS, Glew K et al (2014) Prevalence and Characteristics of school services for high school students with attention-deficit/hyperactivity disorder. School Ment Health 6:264–278
Wolraich ML, Hagan JF Jr, Allan C et al (2019) Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 144:e20192528
Santosh P, Cortese S, Hollis C et al (2023) Remote assessment of ADHD in children and adolescents: recommendations from the European ADHD guidelines group following the clinical experience during the COVID-19 pandemic. Eur Child Adolesc Psychiatry 32:921–935
Canadian Institute for Health Information. Canadian COVID-19 Intervention Timeline. https://www.cihi.ca/en/canadian-covid-19-intervention-timeline. Accessed 15 Nov 2023
Saunders NR, Kurdyak P, Stukel TA et al (2022) Utilization of physician-based mental health care services among children and adolescents before and during the COVID-19 pandemic in Ontario. Canada JAMA Pediatr 176:e216298
Chang A, Chaudhry S, McCormack D et al (2022) Impact of the COVID-19 controlled drugs and substances act exemption on pharmacist prescribing of opioids, benzodiazepines and stimulants in Ontario: a cross-sectional time-series analysis. Can Pharm J (Ott) 155:326–333
Piovani D, Clavenna A, Bonati M (2019) Prescription prevalence of psychotropic drugs in children and adolescents: an analysis of international data. Eur J Clin Pharmacol 75:1333–1346
Bachmann CJ, Wijlaars LP, Kalverdijk LJ et al (2017) Trends in ADHD medication use in children and adolescents in five western countries, 2005–2012. Eur Neuropsychopharmacol 27:484–493
Stevens JR, Wilens TE, Stern TA (2013) Using stimulants for attention-deficit/hyperactivity disorder: clinical approaches and challenges. Prim Care Companion CNS Disord. https://doi.org/10.4088/PCC.12f01472
Feldman ME, Charach A, Bélanger SA (2018) ADHD in children and youth: part 2-treatment. Paediatr Child Health 23:462–472
Thomas R, Mitchell GK, Batstra L (2013) Attention-deficit/hyperactivity disorder: are we helping or harming? BMJ 347:f6172
Moran LV, Ongur D, Hsu J et al (2019) Psychosis with methylphenidate or amphetamine in patients with ADHD. N Engl J Med 380:1128–1138
Eiland LS, Bell EA, Erramouspe J (2014) Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children. Ann Pharmacother 48:1350–1355
Fay TB, Alpert MA (2019) Cardiovascular effects of drugs used to treat attention-deficit/hyperactivity disorder part 2: impact on cardiovascular events and recommendations for evaluation and monitoring. Cardiol Rev 27:173–178
Zhang C, Spence O, Reeves G et al (2021) Cardiovascular risk of concomitant use of atypical antipsychotics and stimulants among commercially insured youth in the United States. Front Psychiatry 12:640244
Alrwisan AA, Wei YJ, Brumback BA et al (2019) Concomitant use of quinolones and stimulants and the risk of adverse cardiovascular symptoms: a retrospective cohort study. Pharmacotherapy 39:1167–1178
Lemelin M, Boukhris T, Zhao JP, Bérard A (2021) Prevalence and determinants of attention deficit/hyperactivity disorder (ADHD) medication use during pregnancy: results from the Quebec pregnancy/children cohort. Pharmacol Res Perspect 9:e00781
Louik C, Kerr S, Kelley KE, Mitchell AA (2015) Increasing use of ADHD medications in pregnancy. Pharmacoepidemiol Drug Saf 24:218–220
Anderson KN, Ailes EC, Danielson M et al (2018) Attention-deficit/hyperactivity disorder medication prescription claims among privately insured women aged 15–44 Years—United States, 2003–2015. MMWR Morb Mortal Wkly Rep 67:66–70
Anderson KN, Dutton AC, Broussard CS et al (2020) ADHD medication use during pregnancy and risk for selected birth defects: national birth defects prevention study, 1998–2011. J Atten Disord 24:479–489
Huybrechts KF, Bröms G, Christensen LB et al (2018) Association between methylphenidate and amphetamine use in pregnancy and risk of congenital malformations: a cohort study from the international pregnancy safety study consortium. JAMA Psychiat 75:167–175
Bang Madsen K, Robakis TK, Liu X et al (2023) In utero exposure to ADHD medication and long-term offspring outcomes. Mol Psychiatry 28:1739–1746
Li L, Sujan AC, Butwicka A et al (2020) Associations of prescribed ADHD medication in pregnancy with pregnancy-related and offspring outcomes: a systematic review. CNS Drugs 34:731–747
American College Health Association. American College Health Association-National College Health Assessment II: Canadian Reference Group Data Report Spring 2013. https://www.acha.org/documents/ncha/ACHA-NCHA-II_CANADIAN_ReferenceGroup_DataReport_Spring2013.pdf. Accessed 14 Nov 2023
American College Health Association. American College Health Association-National College Health Assessment II: Canadian Reference Group Data Report Spring 2016. https://www.acha.org/documents/ncha/NCHA-II%20SPRING%202016%20CANADIAN%20REFERENCE%20GROUP%20DATA%20REPORT.pdf. Accessed 14 Nov 2023.
Faraone SV, Rostain AL, Montano CB, Mason O, Antshel KM, Newcorn JH (2020) Systematic review: nonmedical use of prescription stimulants: risk factors, outcomes, and risk reduction strategies. J Am Acad Child Adolesc Psychiatry 59:100–112
Bliddal M, Rasmussen L, Andersen JH et al (2023) Psychotropic medication use and psychiatric disorders during the COVID-19 pandemic among Danish children, adolescents, and young adults. JAMA Psychiat 80:176–180
Leong C, Katz LY, Bolton JM et al (2022) Psychotropic drug use in children and adolescents before and during the COVID-19 pandemic. JAMA Pediatr 176:318–320
Gimbach S, Vogel D, Fried R et al (2023) The impact of the COVID-19 pandemic on ADHD medicine consumption in 47 countries and regions. Eur Neuropsychopharmacol 73:24–35
Statistics Canada. Focus on Geography Series, 2016 Census. https://www12.statcan.gc.ca/census-recensement/2016/as-sa/fogs-spg/Index-eng.cfm. Accessed 30 Aug 2023
Canadian Institute for Health Information. Canadian COVID-19 Intervention timeline—Data tables. Ottawa, ON: CIHI, 2022
Han JY, Breton C. Have provinces put students first during COVID?. https://policyoptions.irpp.org/magazines/february-2022/have-provinces-put-schools-first-during-covid/. Accessed 31 Aug 2023
Williams JI, Young WA (1996) A summary of studies on the quality of health care administrative databases in Canada. In: Goel V, Williams JI, Anderson GM et al (eds) Patterns of health care in Ontario: the ICES practice atlas, 2nd edn. Canadian Medical Association, Ottawa, pp 339–345
Schull MJ, Azimaee M, Marra M et al (2020) ICES: data, discovery, better health. Int J Popul Data Sci 4:1135
Austin PC, Grootendorst P, Anderson GM (2007) A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med 26:734–753
Martins D, Greaves S, Tadrous M, Shearer D, et al (2018) Landscape of prescription stimulant use: patterns, trends and geographic variation in Ontario, Canada. 2018. https://doi.org/10.31027/ODPRN.2018.01
Bai J, Perron P (1998) Estimating and testing linear models with multiple structural changes. Econometrica 66:47–78
Bernal JL, Cummins S, Gasparrini A (2017) Interrupted time series regression for the evaluation of public health interventions: a tutorial. Int J Epidemiol 46:348–355
Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D (2002) Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 27:299–309
Ministry of Health and Long-Term Care. OHIP+: Children and youth Pharmacare key facts for prescribers. (2023). https://www.afhto.ca/wp-content/uploads/ohip_prescriber-002.pdf. Accessed 30 Aug 2023
Cumby RE, Huizinga J (1992) Testing the autocorrelation structure of disturbances in ordinary least squares and instrumental variables regression. Econometrica 60:185–195
Newey WK, West KD (1987) A simple, positive semi-definite, heteroskedasticity and autocorrelation consistent covariance matrix. Econometrica 55:703e8
Coghill DR, Caballero B, Sorooshian S, Civil R (2014) A systematic review of the safety of lisdexamfetamine dimesylate. CNS Drugs 28:497–511
Wood SJ, Ilomäki J, Gould J et al (2023) Dispensing of psychotropic medications to Australian children and adolescents before and during the COVID-19 pandemic, 2013–2021: a retrospective cohort study. Med J Aust 219:18–25
Danielson ML, Bohm MK, Newsome K et al (2023) Trends in stimulant prescription fills among commercially insured children and adults—United States, 2016–2021. MMWR Morb Mortal Wkly Rep 72:327–332
Bannett Y, Dahlen A, Huffman LC, Feldman HM (2022) Primary care diagnosis and treatment of attention-deficit/hyperactivity disorder in school-age children: trends and disparities during the COVID-19 pandemic. J Dev Behav Pediatr 43:386–392
Gershon J (2002) A meta-analytic review of gender differences in ADHD. J Atten Disord 5:143–154
Young S, Adamo N, Ásgeirsdóttir BB et al (2020) Females with ADHD: An expert consensus statement taking a lifespan approach providing guidance for the identification and treatment of attention-deficit/ hyperactivity disorder in girls and women. BMC Psychiatry 20:404
Statistics Canada. Working from home during the COVID-19 pandemic, April 2020–June 2021. https://www150.statcan.gc.ca/n1/daily-quotidien/210804/dq210804b-eng.htm. Accessed 30 Aug 2023
Statistics Canada. School closures and COVID-19: an interactive tool. https://www150.statcan.gc.ca/n1/pub/71-607-x/71-607-x2021009-eng.htm#a1-1. Accessed 31 Aug 2023
Coker TR, Elliott MN, Toomey SL et al (2016) Racial and ethnic disparities in ADHD diagnosis and treatment. Pediatrics 138:e20160407
Stevens J, Harman JS, Kelleher KJ (2005) Race/ethnicity and insurance status as factors associated with ADHD treatment patterns. J Child Adolesc Psychopharmacol 15:88–96
Acknowledgements
This study was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health (MOH) and the Ministry of Long-Term Care (MLTC). Parts of this material are based on data and/or information compiled and provided by CIHI and the Ontario Ministry of Health. The analyses, conclusions, opinions and statements expressed herein are solely those of the authors and do not reflect those of the funding or data sources; no endorsement is intended or should be inferred. This document used data adapted from the Statistics Canada Postal CodeOM Conversion File, which is based on data licensed from Canada Post Corporation, and/or data adapted from the Ontario Ministry of Health Postal Code Conversion File, which contains data copied under license from ©Canada Post Corporation and Statistics Canada. We thank IQVIA Solutions Canada Inc. for use of their Drug Information File.
Funding
This study was funded by the Canadian Institutes of Health Research (funding reference number 468530). Tara Gomes holds a Canada Research Chair in Drug Policy Research and Evaluation. David Juurlink is supported by an award from the Mak Pak Chiu and Mak-Soo Lai Hing Chair in General Internal Medicine, University of Toronto.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. Data analysis was performed by Tony Antoniou. The first draft of the manuscript was written by Tony Antoniou and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Competing interests
Melanie Penner has received consulting fees for unrelated work the Government of Nova Scotia. Mina Tadrous has received consulting fees for unrelated work from Green Shield Canada and the Canadian Agency for Drugs and Technologies in Health. Tara Gomes has received funding from the Ontario MOH and the Ontario College of Pharmacists.
Conflicts of interest
Melanie Penner has received consulting fees for unrelated work the Government of Nova Scotia. Mina Tadrous has received consulting fees for unrelated work from Green Shield Canada and the Canadian Agency for Drugs and Technologies in Health. Tara Gomes has received funding from the Ontario MOH and the Ontario College of Pharmacists.
Ethics approval and consent to participate
ICES is an independent, non-profit research institute whose legal status under Ontario’s health information privacy law allows it to collect and analyze health care and demographic data, without consent, for health system evaluation and improvement. ICES is a prescribed entity under Sect. 45 of Ontario’s Personal Health Information Protection Act. Section 45 authorizes ICES to collect personal health information, without consent, for the purpose of analysis or compiling statistical information with respect to the management of, evaluation or monitoring of, the allocation of resources to or planning for all or part of the health system. Projects conducted under Sect. 45, by definition, are exempt from and do not require review by a Research Ethics Board. This project was conducted under Sect. 45, and approved by ICES’ Privacy and Compliance Office.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Antoniou, T., Pajer, K., Gardner, W. et al. Impact of COVID-19 pandemic on prescription stimulant use among children and youth: a population-based study. Eur Child Adolesc Psychiatry (2024). https://doi.org/10.1007/s00787-023-02346-x
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00787-023-02346-x